(promotional interactions between drug representatives and physicians). We start with a theoretical framework in which … pharmaceutical firms target detailing visits to physicians who potentially learn about drug quality and prescribe it to their …

positive. The literature written by physicians about pharmaceutical marketing and promotion generally focuses on the harmful … aspects of promotion, and misses the benefits. This suspected harm occurs because physicians who have contact with … optimism of sales representatives. Physicians might be self selected to interact with representatives promoting drugs that the …

Physicians commonly receive marketing-related transfers from drug firms. We examine the impact of these relationships … fading out within a year. A marketing payment also leads physicians to begin treating cancer patients with lower expected …

Physicians' relationships with the pharmaceutical industry have recently come under public scrutiny, particularly in … indicate that both the number and the dollar- value of marketing visits increase physicians' patented opioid claims …

manufacturers and physicians are uncertain about drug qualities. Our model assumes (i) a representative opinion leader is … (ii) manufacturers use detailing as a means to build/maintain the measure of physicians who are informed of the current … detailing to the current information sets and the measures of well-informed physicians. To illustrate the empirical implications …